AnaptysBio, Inc. (ANAB) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Anupam Rama
JPMorgan Chase & Co, Analysis Division

Welcome, everybody, to the forty fourth Annual JPMorgan Healthcare Convention. My title is Anupam Rama. I’m one of many senior biotech analysts right here at JPMorgan. I am joined by my squad, Rati Pinhe, Priyanka Grover and Pleasure Shao. Our subsequent presenting firm is AnaptysBio and presenting on behalf of the corporate, we have now CEO, Dan Faga. Dan?

Daniel Faga
President, CEO & Director

Whats up, everybody. Thanks for having me be a part of at this time, Anupam. These are our forward-looking statements. That is going to be a transformational 12 months for Anaptys. In September, we introduced — September 2025, we introduced the intention to separate into 2 companies by means of the course of this 12 months, and that’s more likely to occur within the second quarter at this level. The two companies are generically known as Biopharma Co and Royalty Administration Co presently.

Biopharma Co will likely be anchored by 3 scientific property. The working enterprise will likely be pushed by means of ANB033. We’re enrolling sufferers within the celiac trial in Section Ib, and we introduced into this weekend that we’re initiating a second trial in Section Ib in EoE. Rosnilimab is a pathogenic depleter or depleter of pathogenic T cells. We had constructive Section IIb leads to our arthritis trial in 2025. And over the subsequent 6 months, we’ll be exploring the way to transfer ahead by means of Section III, together with securing strategic or monetary capital to run the Section III, and we have now an finish of Section II assembly with the FDA over the subsequent quarter. ANB033 is in ongoing Section Ia research.